Cargando…
Darbepoetin alfa is more potent in vivo and can be administered less frequently than rHuEPO
doi:10.1038/sj.bjc.6600506 www.bjcancer.com © (2002) Cancer Research UK
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2002
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376125/ http://dx.doi.org/10.1038/sj.bjc.6600506 |